Chemistry:AB-103
AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil.[1] It is used topically.[1] The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness.[1][2][3][4] It was originated by Applied Biology and is under development by Safety Shot.[1] As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia.[1] It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then.[1] The chemical structure of AB-103 does not yet appear to have been disclosed.[1]
See also
- List of investigational hair loss drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "AB 103". 27 February 2024. https://adisinsight.springer.com/drugs/800052659.
- ↑ "Minoxidil in the treatment of androgenetic alopecia". Dermatologic Therapy 31 (5). September 2018. doi:10.1111/dth.12686. PMID 30155952.
- ↑ "Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia". Dermatologic Therapy 27 (4): 252–254. 2014. doi:10.1111/dth.12130. PMID 24773771.
- ↑ "Clinical utility and validity of minoxidil response testing in androgenetic alopecia". Dermatologic Therapy 28 (1): 13–16. 2015. doi:10.1111/dth.12164. PMID 25112173.
 |  |
